There are few specific indications for<unk> . These generally are limited to the treatment of deficiencies of coagulation proteins for which specific factor concentrates are unavailable or undesirable. A usual dose of plasma is 10–20 mL/kg recipient weight. Indications for the use of<unk>  include the following: *Replacement of isolated factor deficiencies:<unk>  is used to treat rare bleeding disorders when specific factor concentrates are not available.<unk>  is the usual treatment for factor V deficiency. *Reversal of warfarin effect: WarfarinPatients who are anticoagulated with warfarin are deficient in the functional vitamin K dependent coagulation factors II, VII, IX, and X, as well as proteins C and S. These functional deficiencies can be reversed by the administration of vitamin K. For anticoagulated patients who are actively bleeding or who require emergency surgery, prothrombin complex concentrate (ideally, four factor PCCs) should be used if available.<unk> /PF24/thawed plasma should only be used if more effective alternative treatments are not available. The ASA task force recommends starting with 5–8 mL/kg of<unk>  for warfarin reversal and rechecking laboratory values. *Use in antithrombin III deficiency:<unk>  can be used as a source of antithrombin III in patients who are deficient of this inhibitor and are undergoing surgery or who require heparin for treatment of thrombosis. There are purified, human derived, as well as recombinant forms of antithrombin III available in the US. *Treatment of immunodeficiencies:<unk>  is useful in infants with secondary immunodeficiency associated with severe protein-losing enteropathy and in whom total parenteral nutrition is ineffectual.<unk>  also can be used as a source of immunoglobulin for children and adults with humoral immunodeficiency. However, the development of a purified immune globulin for intravenous use (i.e., IVIG) largely has replaced<unk>  *Treatment of thrombotic thrombocytopenic purpura: Therapeutic plasma exchange with<unk> /PF24 or thawed plasma as the replacement fluid is considered the treatment of choice for patients with proven or suspected thrombotic thrombocytopenic purpura (TTP).<unk>  is not recommended unless there is ongoing bleeding or there is a significant blood clotting problem. That is,<unk>  is not used in people to reverse warfarin if there is no bleeding, even for an INR > 9 unless they need urgent surgery. It is also not used in elective surgery, or non-emergency surgery. Thawed plasma is made from<unk>  or PF24 and kept refrigerated (at 1–6 °C) after thawing can be stored for 5 days post thaw. Prophylactic plasma transfusions might have an effect for people that suffer from a blood clotting disorder and receive an invasive procedure. For people that suffer from a blood clotting disorder and receive a planned invasive non-cardiac procedure it is not certain if prophylactic plasma transfusions improve all-cause mortality up to 30 days, major bleeding within 24 hours, number of transfusions per participants within one week, number of individuals requiring a transfusion within one week and serious adverse events measured by plasma-related complications within 24 hours. Different triggers for<unk>  may have little to no effect on major bleeding within 24 hours and serious adverse events measured by plasma transfusion-related complications within 24 hours. Furthermore, different triggers for<unk>  may reduce the number of individuals requiring a transfusion within 7 days.
Fresh frozen plasma
Cryoprecipitate
Pentoxyverine
Protamine
Platelet-rich plasma
Neohemocyte
Packed red blood cells
Protamine sulfate